2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
2022 | Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
| IMMUNE NETWORK |
2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2021 | Therapeutic Singing as a Swallowing Intervention in Head and Neck Cancer Patients With Dysphagia
| INTEGRATIVE CANCER THERAPIES |
2021 | Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2021 | Role and Function of O-GlcNAcylation in Cancer
| CANCERS |
2021 | Dysregulation of T FH-B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
| NATURE COMMUNICATIONS |
2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
2021 | Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
2021 | Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy
| CANCERS |
2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
2021 | Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
| MOLECULES AND CELLS |
2021 | Clinical Insights Into Novel Immune Checkpoint Inhibitors
| FRONTIERS IN PHARMACOLOGY |
2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
2021 | Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
| SCIENTIFIC REPORTS |
2021 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques
| FRONTIERS IN ONCOLOGY |
2021 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma | JOURNAL OF HEPATOLOGY |
2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
2020 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | JOURNAL OF CLINICAL ONCOLOGY |
2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
2020 | Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling | CANCER IMMUNOLOGY RESEARCH |
2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
2020 | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01)
| BMC CANCER |
2020 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC | CANCER DISCOVERY |
2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2020 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study | JOURNAL OF CLINICAL ONCOLOGY |
2020 | Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
| CANCERS |
2020 | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | JCI INSIGHT |
2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
2020 | The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression | CANCER RESEARCH |
2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
2020 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
| BMC CANCER |
2020 | Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
| IMMUNE NETWORK |
2020 | Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
| GENOME MEDICINE |
2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
| PLOS ONE |
2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| SCIENTIFIC REPORTS |
2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| SCIENTIFIC REPORTS |
2019 | Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |